Toxicological research on CYP2E1 involves various approaches, including in vitro studies using liver microsomes or recombinant enzymes, and in vivo studies in animal models. These studies aim to elucidate enzyme kinetics, identify substrates and inhibitors, and assess the impact of genetic variations. Additionally, biomarkers of CYP2E1 activity, such as its metabolic products, are used in clinical and epidemiological studies to evaluate exposure and susceptibility to toxicants.
